Hussman Strategic Advisors Inc. Acquires Shares of 31,500 ANI Pharmaceuticals, Inc. $ANIP

Hussman Strategic Advisors Inc. acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the fourth quarter, Holdings Channel reports. The fund acquired 31,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,487,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Artemis Investment Management LLP acquired a new stake in ANI Pharmaceuticals in the fourth quarter valued at approximately $1,706,000. Vanguard Group Inc. lifted its holdings in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares in the last quarter. Round Rock Advisors LLC lifted its holdings in shares of ANI Pharmaceuticals by 63.8% in the fourth quarter. Round Rock Advisors LLC now owns 8,076 shares of the specialty pharmaceutical company’s stock valued at $638,000 after purchasing an additional 3,146 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 30.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock valued at $86,000 after purchasing an additional 253 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its holdings in shares of ANI Pharmaceuticals by 5.7% in the fourth quarter. State of Alaska Department of Revenue now owns 10,522 shares of the specialty pharmaceutical company’s stock valued at $830,000 after purchasing an additional 565 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Finally, Guggenheim raised their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 3,162 shares of the firm’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $71.64, for a total value of $226,525.68. Following the completion of the sale, the insider directly owned 91,309 shares of the company’s stock, valued at $6,541,376.76. This trade represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $74.91, for a total value of $357,470.52. Following the completion of the transaction, the senior vice president owned 38,730 shares of the company’s stock, valued at approximately $2,901,264.30. This trade represents a 10.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 27,860 shares of company stock valued at $2,111,581. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $80.39 on Friday. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. The business has a fifty day simple moving average of $76.36 and a two-hundred day simple moving average of $81.24. ANI Pharmaceuticals, Inc. has a 1 year low of $56.71 and a 1 year high of $99.50. The company has a market capitalization of $1.80 billion, a P/E ratio of 23.93 and a beta of 0.46.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.